Sangui Biotech International Inc. Reports Sales Results for the Year 2016; Provides Earnings Guidance for the First Quarter of 2017
October 13, 2016 at 06:50 pm IST
Share
Sangui Biotech International Inc. reported sales results for the year 2016. For the year, the company reported sales of USD 48,000 compared to USD 127,000 a year ago. This decline was attributable to a decrease in license revenues due to lower turnover of the wound treatment product Granulox.
For the first quarter of 2017, for the company expects revenues from royalty income of approximately USD 10 during the first quarter of fiscal year 2017.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.